Brief: Adicet Bio Q3 Basic EPS USD -1.16
08/11/2023 21:10
Nov 08 (Reuters) - Adicet Bio Q3 operating expenses USD 52.262 million. * Q3 net income USD -49.885 million * Q3 operating income USD -52.262 million
Recent news on ADICET Bio
See all newsNASDAQ RESUMED AT 09:35 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Brief: Adicet Bio Announces Positive Safety And Efficacy Data From Prula-Cel (Formerly Adi-001) Study In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis
Brief: Adicet Bio Announces FDA Clearance Of Ind Application For Adi-212
Adicet Bio, Inc. Reports Results For The Quarter Ended June 30: Earnings Summary